Herantis Pharma Oyj

January 28, 2025 I Herantis Pharma Plc (“Herantis”), a company developing disease-modifying therapies for Parkinson’s disease, is pleased to announce an update of the ongoing Phase 1b clinical trial of HER-096: The Phase 1b clinical trial, Part 2, is a randomized, double-blind, placebo-controlled trial: The study takes place in Turku and Helsinki, Finland conducted by the contract research organization Clinical Research Services Turku – CRST Oy. More information about participation into the study can be found on the website: The trial is registered at ClinicalTrials.gov here: About HER-096 HER-096 is an engineered peptidomimetic molecule designed to mimic the activity of CDNF, a protein that promotes cell survival and functional recovery of neurons. HER-096 modulates the Unfolded Protein Response (UPR) pathway, the regulation of which is essential in restoring the cell protein balance (proteostasis) and preventing the processes leading to, e.g., cytotoxic protein aggregation and neuronal cell death in the brain. In addition, HER-096 alleviates inflammation in the affected brain area. Thanks to its multimodal mechanism of action, Herantis’ HER-096 has the potential to stop the progression of Parkinson’s disease and significantly improve patients’ quality of life. About Herantis Pharma Plc Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The primary aim of the ongoing Phase 1b clinical trial is to show that repeated subcutaneous doses of HER-096 are safe and well-tolerated in patients with Parkinson’s disease. The Phase 1a clinical trial, completed in late 2023, demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in healthy volunteers. Herantis are listed on the Nasdaq First North Growth Market Finland. Company website: www.herantis.com SOURCE: Herantis Pharma